Behavioral effects of neuropeptides in rodent models of depression and anxiety

Peptides

Volumn 31, Issue 4, 2010, Pages 736-756

  Rotzinger, Susan ^a   Lovejoy, David A ^a   Tan, Laura A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal models; Anxiety; Cholecystokinin; Corticotropin releasing factor; Depression; Galanin; Neuropeptide Y; Oxytocin; Receptor antagonists; Stress; Substance P; Teneurin; Tyr MIF 1; Urocortin; Vasopressin

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARGIPRESSIN; BENZODIAZEPINE DERIVATIVE; BRAIN PEPTIDE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; ENDOMORPHIN 1; ENDOMORPHIN 2; GALANIN; IMIPRAMINE; NETAMIFTIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; OXYTOCIN; SR 149415; SUBSTANCE P; TENEURIN C TERMINAL ASSOCIATED PEPTIDE; TYROSYLPROLYLLEUCYLGLYCINAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROCORTIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ANXIETY DISORDER; CONFLICT; DEFENSIVE BEHAVIOR; DEPRESSION; DRUG TARGETING; EXPERIMENTAL MODEL; EXPLORATORY BEHAVIOR; FEAR; IN VIVO STUDY; MOOD DISORDER; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SOCIAL BEHAVIOR;

ANIMALS; ANXIETY; ARGININE VASOPRESSIN; BEHAVIOR, ANIMAL; CHOLECYSTOKININ; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DISEASE MODELS, ANIMAL; GALANIN; HUMANS; MSH RELEASE-INHIBITING HORMONE; NEUROPEPTIDE Y; NEUROPEPTIDES; NEUROPSYCHOLOGICAL TESTS; OXYTOCIN; SOCIAL BEHAVIOR; UROCORTINS;

ANIMALIA; RODENTIA;

EID: 77649237004     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.12.015     Document Type: Review

References (237)

1. Adams J.B., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 15 (1995) 428-434
2. Al Chawaf A., St Amant K., Belsham D., and Lovejoy D.A. Regulation of neurite growth in immortalized mouse hypothalamic neurons and rat hippocampal primary cultures by teneurin C-terminal-associated peptide-1. Neuroscience 144 (2007) 1241-1254
3. Al Chawaf A., Xu K., Tan L., Vaccarino F.J., Lovejoy D.A., and Rotzinger S. Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1). Peptides 28 (2007) 1406-1415
4. Anisman H., Suissa A., and Sklar L.S. Escape deficits induced by uncontrollable stress: antagonism by dopamine and norepinephrine agonists. Behav Neural Biol 28 (1980) 34-47
5. Appenrodt E., Schnabel R., and Schwarzberg H. Vasopressin administration modulates anxiety-related behavior in rats. Physiol Behav 64 (1998) 543-547
6. Arborelius L., Owens M.J., Plotsky P.M., and Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160 (1999) 1-12
7. Arletti R., and Bertolini A. Influence of protease inhibitors on the antidepressant activity of oxytocin. Neuropeptides 10 (1987) 241-248
8. Arletti R., and Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci 41 (1987) 1725-1730
9. Armario A., Escorihuela R.M., and Nadal R. Long-term neuroendocrine and behavioural effects of a single exposure to stress in adult animals. Neurosci Biobehav Rev 32 (2008) 1121-1135
10. Asakawa A., Inui A., Momose K., Ueno N., Fujino M.A., and Kasuga M. Endomorphins have orexigenic and anxiolytic activities in mice. Neuroreport 9 (1998) 2265-2267
11. Bacchi F., Mathe A.A., Jimenez P., Stasi L., Arban R., Gerrard P., et al. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 27 (2006) 3202-3207
12. Bakharev V.D., Tikhomirov S.M., and Lozhkina T.K. Psychotropic properties of oxytocin. Neurosci Behav Physiol 16 (1986) 160-164
13. Ballard T.M., Sanger S., and Higgins G.A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412 (2001) 255-264
14. Barr A.M., Kinney J.W., Hill M.N., Lu X., Biros S., Rebek Jr. J., et al. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci Lett 405 (2006) 111-115
15. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., and Benoliel J.J. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 13 (2008) 1079-1092
16. Beiderbeck D.I., Neumann I.D., and Veenema A.H. Differences in intermale aggression are accompanied by opposite vasopressin release patterns within the septum in rats bred for low and high anxiety. Eur J Neurosci 26 (2007) 3597-3605
17. Beinfeld M.C., Meyer D.K., Eskay R.L., Jensen R.T., and Brownstein M.J. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212 (1981) 51-57
18. Beinfeld M.C., and Palkovits M. Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei. Brain Res 238 (1982) 260-265
19. Bing O., Moller C., Engel J.A., Soderpalm B., and Heilig M. Anxiolytic-like action of centrally administered galanin. Neurosci Lett 164 (1993) 17-20
20. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., and Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165 (2008) 617-620
21. Blanchard D.C., Griebel G., and Blanchard R.J. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463 (2003) 97-116
22. Bleickardt C.J., Mullins D.E., Macsweeney C.P., Werner B.J., Pond A.J., Guzzi M.F., et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology (Berl) 202 (2009) 711-718
23. Bocheva A., Dzambazova E., Hadjiolova R., Traikov L., Mincheva R., and Bivolarski I. Effect of Tyr-MIF-1 peptides on blood ACTH and corticosterone concentration induced by three experimental models of stress. Auton Autacoid Pharmacol 28 (2008) 117-123
24. Borsini F., and Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology (Berl) 94 (1988) 147-160
25. Britton K.T., Akwa Y., Spina M.G., and Koob G.F. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 21 (2000) 37-44
26. Brocco M., Dekeyne A., Mannoury la Cour C., Touzard M., Girardon S., Veiga S., et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 18 (2008) 729-750
27. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., and Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6 (1995) 215-222
28. Bujdoso E., Jaszberenyi M., Tomboly C., Toth G., and Telegdy G. Behavioral and neuroendocrine actions of endomorphin-2. Peptides 22 (2001) 1459-1463
29. Bujdoso E., Jaszberenyi M., Tomboly C., Toth G., and Telegdy G. Effects of endomorphin-1 on open-field behavior and on the hypothalamic-pituitary-adrenal system. Endocrine 14 (2001) 221-224
30. Burbach J.P., and Lebouille J.L. Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis. J Biol Chem 258 (1983) 1487-1494
31. Caldwell H.K., Lee H.J., Macbeth A.H., and Young III W.S. Vasopressin: behavioral roles of an "original" neuropeptide. Prog Neurobiol 84 (2008) 1-24
32. Carvalho M.C., Masson S., Brandao M.L., and de Souza Silva M.A. Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin. Peptides 29 (2008) 1191-1200
33. Cassella J.V., and Davis M. Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats. Psychopharmacology (Berl) 87 (1985) 278-282
34. Celis M.E., Taleisnik S., and Walter R. Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc Natl Acad Sci USA 68 (1971) 1428-1433
35. Chaki S., Okubo T., and Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Pat CNS Drug Discov 1 (2006) 1-27
36. Chenu F., Guiard B.P., Bourin M., and Gardier A.M. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 172 (2006) 256-263
37. Crawley J.N. Biological actions of galanin. Regul Pept 59 (1995) 1-16
38. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
39. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29 (2005) 571-625
40. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29 (2005) 547-569
41. Dableh L.J., Yashpal K., Rochford J., and Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507 (2005) 99-105
42. Davis M. Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology (Berl) 62 (1979) 1-7
43. Davis M., Falls W.A., Campeau S., and Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58 (1993) 175-198
44. de Groote L., Penalva R.G., Flachskamm C., Reul J.M., and Linthorst A.C. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J Neurochem 94 (2005) 45-56
45. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 (1999) 79-86
46. Duarte F.S., Testolin R., and De Lima T.C. Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats. Behav Brain Res 154 (2004) 501-510
47. Dunn A.J., and Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res Brain Res Rev 15 (1990) 71-100
48. Ebner K., Rupniak N.M., Saria A., and Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101 (2004) 4280-4285
49. Ebner K., and Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 31 (2006) 251-272
50. Echevarria D.J., Hernandez A., Diogenes A., and Morilak D.A. Administration of the galanin antagonist M40 into lateral septum attenuates shock probe defensive burying behavior in rats. Neuropeptides 39 (2005) 445-451
51. Ehrensing R.H., and Kastin A.J. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression. Am J Psychiatry 135 (1978) 562-566
52. Ehrensing R.H., and Kastin A.J. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study. Arch Gen Psychiatry 30 (1974) 63-65
53. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., and Mebane A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 31 (1994) 227-233
54. Everts H.G., and Koolhaas J.M. Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats. Behav Brain Res 99 (1999) 7-16
55. Feighner J.P., Ehrensing R.H., Kastin A.J., Leonard B.E., Sverdlov L., Nicolau G., et al. A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression. J Affect Disord 61 (2000) 119-126
56. Feighner J.P., Ehrensing R.H., Kastin A.J., Patel A., Sverdlov L., Hlavka J., et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int Clin Psychopharmacol 16 (2001) 345-352
57. Feighner J.P., Sverdlov L., Nicolau G., Abajian H.B., Hlavka J., Freed J.S., et al. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment. Int J Neuropsychopharmacol 6 (2003) 207-213
58. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., Orain D., et al. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology (Berl) 206 (2009) 291-301
59. Fichna J., Janecka A., Piestrzeniewicz M., Costentin J., and do Rego J.C. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 32 (2007) 813-821
60. File S.E. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl) 152 (2000) 105-109
61. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2 (1980) 219-238
62. File S.E., and Hyde J.R. Can social interaction be used to measure anxiety?. Br J Pharmacol 62 (1978) 19-24
63. Fisher A., Mann A., Verma V., Thomas N., Mishra R.K., and Johnson R.L. Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor. J Med Chem 49 (2006) 307-317
64. Floren A., Sollenberg U., Lundstrom L., Zorko M., Stojan J., Budihna M., et al. Multiple interaction sites of galnon trigger its biological effects. Neuropeptides 39 (2005) 547-558
65. Frank E., and Landgraf R. The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol 583 (2008) 226-242
66. Frankland P.W., Josselyn S.A., Bradwejn J., Vaccarino F.J., and Yeomans J.S. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci 17 (1997) 1838-1847
67. Fukunaga H., Takahashi M., Kaneto H., and Yoshikawa M. Effects of Tyr-MIF-1 on stress-induced analgesia and the blockade of development of morphine tolerance by stress in mice. Jpn J Pharmacol 79 (1999) 231-235
68. Gehlert D.R., Shekhar A., Morin S.M., Hipskind P.A., Zink C., Gackenheimer S.L., et al. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 509 (2005) 145-153
69. Geoffroy M., Scheel-Kruger J., and Christensen A.V. Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. Psychopharmacology (Berl) 101 (1990) 371-375
70. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286 (1998) 1007-1013
71. Goyal S.N., Kokare D.M., Chopde C.T., and Subhedar N.K. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats. Pharmacol Biochem Behav 85 (2006) 369-377
72. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?. Pharmacol Ther 82 (1999) 1-61
73. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99 (2002) 6370-6375
74. Griebel G., Simiand J., Stemmelin J., Gal C.S., and Steinberg R. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2 (2003) 191-200
75. Guastella A.J., Howard A.L., Dadds M.R., Mitchell P., and Carson D.S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34 (2009) 917-923
76. Harris J.A., and Westbrook R.F. Benzodiazepine-induced amnesia in rats: reinstatement of conditioned performance by noxious stimulation on test. Behav Neurosci 112 (1998) 183-192
77. Heilig M., McLeod S., Koob G.K., and Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41 (1992) 61-69
78. Heilig M., Soderpalm B., Engel J.A., and Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98 (1989) 524-529
79. Heinrichs M., Baumgartner T., Kirschbaum C., and Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54 (2003) 1389-1398
80. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., and Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27 (2002) 194-202
81. Heinrichs S.C., Menzaghi F., Merlo Pich E., Britton K.T., and Koob G.F. The role of CRF in behavioral aspects of stress. Ann N Y Acad Sci 771 (1995) 92-104
82. Heinrichs S.C., Menzaghi F., Pich E.M., Baldwin H.A., Rassnick S., Britton K.T., et al. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 11 (1994) 179-186
83. Henry B., Vale W., and Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26 (2006) 9142-9152
84. Hernando F., Fuentes J.A., Roques B.P., and Ruiz-Gayo M. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 261 (1994) 257-263
85. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86 (2007) 431-440
86. Hokfelt T., Bartfai T., and Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol 2 (2003) 463-472
87. Hokfelt T., Broberger C., Xu Z.Q., Sergeyev V., Ubink R., and Diez M. Neuropeptides-an overview. Neuropharmacology 39 (2000) 1337-1356
88. Holmes A., Heilig M., Rupniak N.M., Steckler T., and Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24 (2003) 580-588
89. Holsboer F., and Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583 (2008) 350-357
90. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87 (1990) 6728-6732
91. Ishida H., Shirayama Y., Iwata M., Katayama S., Yamamoto A., Kawahara R., et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 17 (2007) 271-280
92. Jones D.N., Kortekaas R., Slade P.D., Middlemiss D.N., and Hagan J.J. The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (Berl) 138 (1998) 124-132
93. Josselyn S.A., Frankland P.W., Petrisano S., Bush D.E., Yeomans J.S., and Vaccarino F.J. The CCKB antagonist, L-365,260, attenuates fear-potentiated startle. Peptides 16 (1995) 1313-1315
94. Kametani H., Nomura S., and Shimizu J. The reversal effect of antidepressants on the escape deficit induced by inescapable shock in rats. Psychopharmacology (Berl) 80 (1983) 206-208
95. Karlsson R.M., Holmes A., Heilig M., and Crawley J.N. Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Pharmacol Biochem Behav 80 (2005) 427-436
96. Kask A., Rago L., and Harro J. Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept 75-76 (1998) 255-262
97. Kask K., Berthold M., and Bartfai T. Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Life Sci 60 (1997) 1523-1533
98. Kastin A.J., Scollan E.L., Ehrensing R.H., Schally A.V., and Coy D.H. Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 9 (1978) 515-519
99. Katz R.J. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav 16 (1982) 965-968
100. Keck M.E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13 (2001) 373-380
101. Kehne J.H., Cassella J.V., and Davis M. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology (Berl) 94 (1988) 8-13
102. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59 (2006) 216-223
103. Khoshbouei H., Cecchi M., Dove S., Javors M., and Morilak D.A. Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol Biochem Behav 71 (2002) 407-417
104. Khoshbouei H., Cecchi M., and Morilak D.A. Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology 27 (2002) 25-34
105. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25 (2005) 11489-11493
106. Klenerova V., Krejci I., Sida P., Hlinak Z., and Hynie S. Modulary effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field. J Physiol Pharmacol 60 (2009) 57-62
107. Kokare D.M., Dandekar M.P., Chopde C.T., and Subhedar N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res 1043 (2005) 107-114
108. Kostowski W., Danysz W., Dyr W., Jankowska E., Krzascik P., Palejko W., et al. MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression. Peptides 12 (1991) 915-918
109. Kozicz T. On the role of urocortin 1 in the non-preganglionic Edinger-Westphal nucleus in stress adaptation. Gen Comp Endocrinol 153 (2007) 235-240
110. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
111. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 37 (1995) 462-466
112. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004) 385-392
113. Krase W., Koch M., and Schnitzler H.U. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 63 (1994) 81-88
114. Kunzel H.E., Zobel A.W., Nickel T., Ackl N., Uhr M., Sonntag A., et al. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37 (2003) 525-533
115. Kuteeva E., Hokfelt T., Wardi T., and Ogren S.O. Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci 65 (2008) 1854-1863
116. Kuteeva E., Wardi T., Hokfelt T., and Ogren S.O. Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur Neuropsychopharmacol 17 (2007) 64-69
117. Kuteeva E., Wardi T., Lundstrom L., Sollenberg U., Langel U., Hokfelt T., et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 33 (2008) 2573-2585
118. Lang P.J., Davis M., and Ohman A. Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61 (2000) 137-159
119. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin. Brain Res 1156 (2007) 152-167
120. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30 (2005) 1883-1894
121. Levy M.I., DeNigris Y., and Davis K.L. Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol Psychiatry 17 (1982) 259-263
122. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98 (2001) 7570-7575
123. Liebsch G., Wotjak C.T., Landgraf R., and Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett 217 (1996) 101-104
124. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46 (1990) 321-340
125. Lovejoy D.A., Al Chawaf A., and Cadinouche M.Z. Teneurin C-terminal associated peptides: an enigmatic family of neuropeptides with structural similarity to the corticotropin-releasing factor and calcitonin families of peptides. Gen Comp Endocrinol 148 (2006) 299-305
126. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., et al. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci USA 102 (2005) 874-879
127. Lundstrom L., Elmquist A., Bartfai T., and Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 7 (2005) 157-180
128. Lyudyno V.I., Abdurasulova I.N., and Klimenko V.M. The role of the neuropeptide galanin in forming type-specific behavioral characteristics. Neurosci Behav Physiol 38 (2008) 93-98
129. Malkani S., and Rosen J.B. Induction of NGFI-B mRNA following contextual fear conditioning and its blockade by diazepam. Brain Res Mol Brain Res 80 (2000) 153-165
130. Malkesman O., Braw Y., and Weller A. Assessment of antidepressant and anxiolytic properties of NK1 antagonists and substance P in Wistar Kyoto rats. Physiol Behav 90 (2007) 619-625
131. Mansbach R.S., Brooks E.N., and Chen Y.L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323 (1997) 21-26
132. Mathe A.A., Husum H., El Khoury A., Jimenez-Vasquez P., Gruber S.H., Wortwein G., et al. Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. Physiol Behav 92 (2007) 226-231
133. Mathew S.J., Price R.B., and Charney D.S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 148C (2008) 89-98
134. Matto V., Harro J., and Allikmets L. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box. J Physiol Pharmacol 48 (1997) 239-251
135. McCarthy M.M., McDonald C.H., Brooks P.J., and Goldman D. An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav 60 (1996) 1209-1215
136. Millan M.J., and Brocco M. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463 (2003) 67-96
137. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., and Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25 (2001) 585-600
138. Mitchell A.J. The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci Biobehav Rev 22 (1998) 635-651
139. Mitsukawa K., Lu X., and Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 65 (2008) 1796-1805
140. Moller C., Sommer W., Thorsell A., and Heilig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology 21 (1999) 507-512
141. Montgomery S.A., Feighner J.P., Sverdlov L., Shrivastava R.K., Cunningham L.A., Kiev A., et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol 9 (2006) 517-528
142. Moreau J.L., Kilpatrick G., and Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport 8 (1997) 1697-1701
143. Nair R.M., Kastin A.J., and Schally A.V. Isolation and structure of hypothalamic MSH release-inhibition hormone. Biochem Biophys Res Commun 43 (1971) 1376-1381
144. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., et al. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 19 (1998) 359-363
145. Neumann I.D. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol 20 (2008) 858-865
146. Neumann I.D., Torner L., and Wigger A. Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats. Neuroscience 95 (2000) 567-575
147. Neumann I.D., Wigger A., Torner L., Holsboer F., and Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol 12 (2000) 235-243
148. Nicolau G., Feighner J.P., Stout R., Hlavka J., Gutierrez M., Ciric S., et al. Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers. Biopharm Drug Dispos 26 (2005) 379-385
149. Nielsen D.M. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?. Life Sci 78 (2006) 909-919
150. Nielsen D.M., Carey G.J., and Gold L.H. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499 (2004) 135-146
151. Ogren S.O., Kuteeva E., Hokfelt T., and Kehr J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 20 (2006) 633-654
152. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A., et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289 (1999) 926-935
153. Olson R.D., Kastin A.J., Olson G.A., King B.M., Von Almen T.K., Berzas M.C., et al. MIF-I suppresses deprivation-induced fluid consumption in rats. Peptides 1 (1980) 353-357
154. Overstreet D.H. Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 32 (2002) 335-348
155. Overstreet D.H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17 (1993) 51-68
156. Overstreet D.H., and Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497 (2004) 49-53
157. Overstreet D.H., and Griebel G. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 82 (2005) 223-227
158. Overstreet D.H., Hlavka J., Feighner J.P., Nicolau G., and Freed J.S. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl) 175 (2004) 303-309
159. Overstreet D.H., Keeney A., and Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol 492 (2004) 195-201
160. Overstreet D.H., knapp D.J., and Breese G.R. Can CRF1 receptor antagonists become antidepressant and/or Anxiolytic Agents?. Drug development research 65 (2005) 191-204
161. Pan W., and Kastin A.J. From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides. Peptides 28 (2007) 2411-2434
162. Pan W., and Kastin A.J. Urocortin and the brain. Prog Neurobiol 84 (2008) 148-156
163. Pande A.C., Greiner M., Adams J.B., Lydiard R.B., and Pierce M.W. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 46 (1999) 860-862
164. Papp M., Vassout A., and Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115 (2000) 19-23
165. Pellow S., and File S.E. Can anti-panic drugs antagonise the anxiety produced in the rat by drugs acting at the GABA-benzodiazepine receptor complex?. Neuropsychobiology 17 (1987) 60-65
166. Petersen E.N., and Lassen J.B. A water lick conflict paradigm using drug experienced rats. Psychopharmacology (Berl) 75 (1981) 236-239
167. Pignatiello M.F., Olson G.A., Kastin A.J., Ehrensing R.H., McLean J.H., and Olson R.D. MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav 32 (1989) 737-742
168. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47 (1978) 379-391
169. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
170. Pucilowski O., Plaznik A., and Kostowski W. MIF-1 facilitates passive avoidance retention. Pol J Pharmacol Pharm 34 (1982) 107-113
171. Pulvirenti L., and Kastin A.J. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats. Eur J Pharmacol 151 (1988) 289-292
172. Qian X., Barsyte-Lovejoy D., Wang L., Chewpoy B., Gautam N., Al Chawaf A., et al. Cloning and characterization of teneurin C-terminus associated peptide (TCAP)-3 from the hypothalamus of an adult rainbow trout (Oncorhynchus mykiss). Gen Comp Endocrinol 137 (2004) 205-216
173. Radulovic J., Ruhmann A., Liepold T., and Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19 (1999) 5016-5025
174. Rajarao S.J., Platt B., Sukoff S.J., Lin Q., Bender C.N., Nieuwenhuijsen B.W., et al. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 41 (2007) 307-320
175. Rataud J., Darche F., Piot O., Stutzmann J.M., Bohme G.A., and Blanchard J.C. Anxiolytic effect of CCK-antagonists on plus-maze behavior in mice. Brain Res 548 (1991) 315-317
176. Redrobe J.P., Dumont Y., Fournier A., and Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26 (2002) 615-624
177. Redrobe J.P., Dumont Y., and Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 71 (2002) 2921-2937
178. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98 (2001) 2843-2848
179. Rezayat M., Roohbakhsh A., Zarrindast M.R., Massoudi R., and Djahanguiri B. Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav 84 (2005) 775-782
180. Ring R.H., Malberg J.E., Potestio L., Ping J., Boikess S., Luo B., et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185 (2006) 218-225
181. Ring R.H., Schechter L.E., Leonard S.K., Dwyer J.M., Platt B.J., Graf R., et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009)
182. Ripoll N., Hascoet M., and Bourin M. The four-plates test: anxiolytic or analgesic paradigm?. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 873-880
183. Risbrough V.B., Hauger R.L., Pelleymounter M.A., and Geyer M.A. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170 (2003) 178-187
184. Rodgers R.J., and Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21 (1997) 801-810
185. Rotzinger S., and Vaccarino F.J. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci 28 (2003) 171-181
186. Rupniak N.M., Webb J.K., Fisher A., Smith D., and Boyce S. The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacology 44 (2003) 516-523
187. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., et al. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci 28 (2008) 893-903
188. Salome N., Stemmelin J., Cohen C., and Griebel G. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 187 (2006) 237-244
189. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Marechal P., Pequeux C., et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 32 (2007) 407-410
190. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93 (1996) 10477-10482
191. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., and Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl) 116 (1994) 56-64
192. Sherrin T., Todorovic C., Zeyda T., Tan C.H., Hon P.W., Zhu Y.Z., et al. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Mol Psychiatry 14 (2009) 291-307
193. Shimazaki T., Iijima M., and Chaki S. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 543 (2006) 63-67
194. Simon N.G., Guillon C., Fabio K., Heindel N.D., Lu S.F., Miller M., et al. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat CNS Drug Discov 3 (2008) 77-93
195. Singh L., Lewis A.S., Field M.J., Hughes J., and Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88 (1991) 1130-1133
196. Slattery D.A., and Neumann I.D. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology (2009)
197. Smagin G.N., Heinrichs S.C., and Dunn A.J. The role of CRH in behavioral responses to stress. Peptides 22 (2001) 713-724
198. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., and Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 77 (2004) 723-729
199. Spiga F., Lightman S.L., Shekhar A., and Lowry C.A. Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons. Neuroscience 138 (2006) 1265-1276
200. Stemmelin J., Lukovic L., Salome N., and Griebel G. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30 (2005) 35-42
201. Stogner K.A., and Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur J Pharmacol 387 (2000) R9-10
202. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hokfelt T., et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 102 (2005) 17489-17494
203. Takahashi L.K., Ho S.P., Livanov V., Graciani N., and Arneric S.P. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902 (2001) 135-142
204. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., and Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci 103 (1989) 648-654
205. Tan L.A., Xu K., Vaccarino F.J., Lovejoy D.A., and Rotzinger S. Repeated intracerebral teneurin C-terminal associated peptide (TCAP)-1 injections produce enduring changes in behavioral responses to corticotropin-releasing factor (CRF) in rat models of anxiety. Behav Brain Res 188 (2008) 195-200
206. Tanaka M., and Telegdy G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res Bull 75 (2008) 509-512
207. Teixeira R.M., and De lima T.C. Involvement of tachykinin NK1 receptor in the behavioral and immunological responses to swimming stress in mice. Neuropeptides 37 (2003) 307-315
208. Teixeira R.M., Duarte F.S., and De Lima T.C. Behavioral and immunological effects of substance P in female and male mice. Pharmacol Biochem Behav 79 (2004) 1-9
209. Teixeira R.M., Santos A.R., Ribeiro S.J., Calixto J.B., Rae G.A., and De Lima T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311 (1996) 7-14
210. Treit D. A comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics. Pharmacol Biochem Behav 36 (1990) 203-205
211. Treit D., Menard J., and Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44 (1993) 463-469
212. Trubiani G., Al Chawaf A., Belsham D.D., Barsyte-Lovejoy D., and Lovejoy D.A. Teneurin carboxy (C)-terminal associated peptide-1 inhibits alkalosis-associated necrotic neuronal death by stimulating superoxide dismutase and catalase activity in immortalized mouse hypothalamic cells. Brain Res 1176 (2007) 27-36
213. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., and Zorrilla E.P. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943 (2002) 142-150
214. Valdez G.R., Zorrilla E.P., Rivier J., Vale W.W., and Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980 (2003) 206-212
215. Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213 (1981) 1394-1397
216. van der Velde C.D. Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness. Peptides 4 (1983) 297-300
217. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17 (1997) 284-292
218. van Megen H.J., Westenberg H.G., den Boer J.A., Slaap B., van Es-Radhakishun F., and Pande A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl) 129 (1997) 243-248
219. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428 (2000) 191-212
220. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., Duffy R.A., Lachowicz J.E., et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27 (2002) 371-379
221. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
222. Versteeg D.H. Neurohypophyseal hormones and brain neurochemistry. Pharmacol Ther 19 (1982) 297-325
223. Vivian J.A., Barros H.M., Manitiu A., and Miczek K.A. Ultrasonic vocalizations in rat pups: modulation at the gamma-aminobutyric acidA receptor complex and the neurosteroid recognition site. J Pharmacol Exp Ther 282 (1997) 318-325
224. Wahlsten D., Metten P., Phillips T.J., Boehm II S.L., Burkhart-Kasch S., Dorow J., et al. Different data from different labs: lessons from studies of gene-environment interaction. J Neurobiol 54 (2003) 283-311
225. Wang H., Wong P.T., Spiess J., and Zhu Y.Z. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 29 (2005) 1361-1373
226. Wang L., Rotzinger S., Al Chawaf A., Elias C.F., Barsyte-Lovejoy D., Qian X., et al. Teneurin proteins possess a carboxy terminal sequence with neuromodulatory activity. Brain Res Mol Brain Res 133 (2005) 253-265
227. Weiss J.M., Bonsall R.W., Demetrikopoulos M.K., Emery M.S., and West C.H. Galanin: a significant role in depression?. Ann N Y Acad Sci 863 (1998) 364-382
228. Wigger A., Sanchez M.M., Mathys K.C., Ebner K., Frank E., Liu D., et al. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 29 (2004) 1-14
229. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16 (1992) 525-534
230. Willner P., Towell A., Sampson D., Sophokleous S., and Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93 (1987) 358-364
231. Wilson J., Watson W.P., and Little H.J. CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Psychopharmacology (Berl) 137 (1998) 120-131
232. Windle R.J., Shanks N., Lightman S.L., and Ingram C.D. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138 (1997) 2829-2834
233. Yamano M., Yuki H., Yasuda S., and Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 292 (2000) 181-187
234. Yoshimura R., Kiyama H., Kimura T., Araki T., Maeno H., Tanizawa O., et al. Localization of oxytocin receptor messenger ribonucleic acid in the rat brain. Endocrinology 133 (1993) 1239-1246
235. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502
236. Zhao Y., Valdez G.R., Fekete E.M., Rivier J.E., Vale W.W., Rice K.C., et al. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther 323 (2007) 846-854
237. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34 (2000) 171-181